# Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck

> **NCT02061631** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 35 (actual)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** DOCETAXEL XRP6976
- **DRUG:** Dexamethasone
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02061631
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-07
- **Final completion:** 2015-10
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2015-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02061631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02061631, "Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02061631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*